Drug Profile
Interleukin-7 gene therapy
Latest Information Update: 28 Nov 2007
Price :
$50
*
At a glance
- Originator Amgen; Boehringer Ingelheim; Freie Universitat Berlin; Henry M. Jackson Foundation for the Advancement of Military Medicine; Walter Reed Army Institute of Research
- Developer Amgen; Freie Universitat Berlin; Henry M. Jackson Foundation for the Advancement of Military Medicine; Nonindustrial source; Walter Reed Army Institute of Research
- Class Antivirals; Cytokine genes; Gene therapies; Interleukins
- Mechanism of Action B cell stimulants; Interleukin 7 stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; HIV infections
Most Recent Events
- 28 Nov 2006 Discontinued - Preclinical for Cancer in Germany (unspecified route)
- 28 Nov 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Nov 2006 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)